OUTCOME OF SYSTEMIC LUPUS ERYTHEMATOSUS IN MINORITIES--NATURE VS NURTURE

Lumina研究是一项纵向的、非干预性的随访研究 系统性红斑狼疮患者的预后。的目标 这项研究是：1)选择一个明确的高加索人队列(C)， 西班牙裔(H)和非裔美国人(A-A) (每组80人)所有SLE中病程在5年或以下的SLE 在UAB和UTHSC被视为门诊或住院患者的患者 休斯顿，以便确定他们的初始状态并跟踪他们 病程和早期结果每隔6个月一次，此后为一段时间 三年了。UAB中心将招收120名患者(60名高加索人和60名 非洲裔美国人)。休斯顿的UTHSC将招收120名患者(80名 拉美裔、20名高加索人和20名非洲裔美国人)，总数为240人 两个中心的狼疮患者。 2)人类白细胞抗原II类基因分型(HLA、DRB1、DRB3、DRB5、DQA1、 DQB1和DPB1等位基因)，其基因剂量 这些患者的III型C4和C2蛋白同型。 3)确定人口、社会经济和文化特征 这些病人。 (4)确定相关的临床参数、疾病表现 (例如，器官系统受累的程度和并存)， 实验室检查(如血细胞计数、尿检、血肌酐、狼疮 抗凝剂)和选定的自身抗体(例如抗核抗体、抗DNA等) 我们认为这些基因的表达可能是由基因介导的； 5)遵循a)数量和严重程度所显示的疾病结果 耀斑的数量，b)疾病活跃度，以SLAM衡量，c)疾病 由SLICC量表衡量的严重程度，d)整体功能状态， E)肾脏存活率，和f)存活率，每两年一次，为期3年。 (6)检验遗传的相对贡献/交互作用， 人口、社会经济、文化和最初的临床和 早期系统性红斑狼疮病程和转归的实验室特征 相依统计分析方法，包括比例风险， 考克斯回归和一般E方程。

The LUMINA Study is a longitudinal, non-intervention follow-up study of the outcome of patients with systemic lupus erythematosus. The goals of this study are: 1) To select a well-defined cohort of Caucasians (C), Hispanics (H) and African Americans (A-A) (80 in each group) with SLE of 5 years or less in duration from all SLE patients seen either as outpatients or inpatients at UAB and UTHSC at Houston in order to ascertain their initial status and follow their course and early outcomes at 6 months intervals thereafter for a period of 3 years. UAB center will enroll 120 patients (60 Caucasians and 60 African-Americans). UTHSC at Houston will enroll 120 patients (80 Hispanics, 20 Caucasians, and 20 African-Americans), for a total of 240 lupus patients in both centers. 2) To determine the HLA class II genotypes (HLA,DRB1, DRB3, DRB5, DQA1, DQB1 and DPB1 alleles) by oligotyping, the gene dosage thereof, and Class III C4 and C2 protein allotypes in these patients. 3) To determine the demographic, socioeconomic and cultural features of these patients. (4) To determine pertinent clinical parameters, disease manifestations (e.g., extent of organ system involvement and co-morbidities), laboratory features (e.g. CBC, urinalysis, serum creatinine, lupus anticoagulant) and selected autoantibodies (e.g. ANA, anti-DNA, etc.) whose expression we feel may be genetically mediated; 5) To follow disease outcome as manifested by a) the number and severity of flares, b) disease activity as measured by the SLAM, c) disease severity as measured by the SLICC scale, d) overall functional status, e) renal survival, and f) survival, biannually over a 3 year period. (6) To examine the relative contributions/interactions of genetic, demographic, socioeconomic, cultural, and initial clinical and laboratory features on the course and outcome of early SLE through time dependent statistical analytic approaches including proportional hazard, Cox regression, and General E equations.